Idan ka ɗauki maganin maye gurbin maganin hormone na Synthroid, zaka iya ji game da karar da aka yi a kotu wanda aka sanya wa kamfanin Knoll Pharmaceuticals, da kuma kamfanin BASF na iyaye, a ƙarshen 1990s. An yanke hukunci ne, amma yana da muhimmanci mu san game da shi, a matsayin ɓangare na tarihin wannan magunguna mai suna levothyroxine.
Wasu Tarihi
A cikin shekarun 1990s, Knoll Pharmaceuticals ya kirkiri Synthroid. Synthroid ya bayar da rahoton kashi 85 cikin 100 na kasuwa na levothyroxine a shekarar 1997. An hada farashin Synthroid sosai fiye da masu fafatawa, kuma wakilan tallace-tallace da littattafai na tallata sun ce farashin mafi girma ya dace yayin da miyagun ƙwayoyi ke da kyau fiye da masu fafatawa. Kamfanin ya fara tabbatar da wannan tare da bincike kuma ya ba da izinin binciken don nuna cewa Synthroid ya kasance a cikin asibiti mafi kyau fiye da sauran nau'in-iri da kuma kwayoyin levothyroxine.
Binciken, wanda Betty Dong, MD, ya gudanar, ya gano cewa Synthroid ya kasance daidai, amma ba mai tsayi ba, don yin amfani da kwayoyi levothyroxine. A wannan lokacin, Knoll ya jawo nazarin kuma ya hana wallafa abubuwan da aka samu a cikin mujallu na likita. A lokacin da Knoll ya yi watsi da shi, Dokta Dong ya fara binciken da aka buga.
Bayan da aka gudanar da bincike na Dr. Dong, an gabatar da shari'ar a cikin madadin masu amfani waɗanda suka yi imanin cewa an batar da su don su biya karin don Synthroid.
An gudanar da aikin na shekarar 2000 a shekarar 2000, kuma an biya kudaden ƙarshe ga masu amfani da shi a shekara ta 2003. (Lura: Masu amfani waɗanda ba su da fayil a wancan lokacin ba zasu iya samun kudi ba.)
Basis na Class Action Kick
Kotun ta fito ne daga binciken, wanda ya fara a shekara ta 1996, wanda ya yi zargin cewa Knoll Pharmaceuticals da BASF mahaifa sun keta dokokin kare kaya ta hanyar yin ƙoƙari don hana wallafa sakamakon binciken da Dr. Dong ya yi, wanda ya nuna a fili cewa nau'in mai suna levothyroxine kwayoyi sun kasance daidai da Synthroid alama a cikin sharuddan tasiri da kuma aminci ga thyroid marasa lafiya.
Dokta Dong ya shaidawa jarida na Ƙungiyar lafiya ta Amirka cewa binciken da aka yi wa kamfanin likitancin ya shafe shekaru shida. Har ila yau, Knoll ya yi la'akari da wannan littafin don dakatar da buga wannan binciken.
Kotu ta yi zargin cewa masu kare su sun ɓoye ko magance su game da magungunan kwayar halitta da kuma kwayoyin levothyroxine, sun nuna cewa ba su da kama da Synthroid , saboda haka sun caje wa masu amfani fiye da yadda za su ciyar idan sun san akwai tsada hanyoyi.
Synthroid Class Action Ƙungiyoyin Tsaro
Sakamakon farko da aka yi da Knoll ya kasance kimanin dala biliyan 8.5. A wannan lokacin a shekara ta 2000, an kiyasta kasuwar levothyroxine kimanin dala miliyan 600 a kowace shekara. Duk da haka, an gudanar da wannan shiri ne na kasa da kasa da wadanda ake bukata.
A ranar Talata, Agusta 8, 2000, Kamfanin Knoll Pharmaceutical Company ya bayyana cewa Alkalin Elaine Bucklo na Kotun Koli na Amurka na Arewacin Jihar Illinois ya ba da amincewa da yarjejeniyar sulhu na aikin Synthroid.
Sakamakon kuɗin daga asusun ajiyar kuɗi, wanda daga Yuni 30, 2000, ya ƙunshi kimanin dala miliyan 91 da bashi (ƙananan lauyoyi da katunan lauyoyi) an sanya su biya ga masu amfani da suka sanya su a matsayin ɓangare na shari'a kuma sun amince su saki dukkanin iƙirari da Knoll.
Kusan kusan dolar Amirka miliyan 46 da bashi (ƙananan lauyoyin lauyoyi da katunan kuɗi) dole ne a biya wa ɗaliban masu biyan haraji.
A lokacin, Knoll ya kiyasta cewa mutane 778,000 za su sami biyan kuɗin kimanin $ 111 kowace idan sun fara shan Synthroid kafin Janairu 1, 1995, kuma kimanin $ 74 kowannensu idan sun fara shan Synthroid bayan Janairu 1, 1995. An biya kuɗin a gaban karshen 2000 idan ba a aika da takaddama ba. An aika da takaddama, duk da haka, ana ƙara jinkirta ƙauyuka.
A ƙarshe, an aika magunguna zuwa marasa lafiya a farkon shekara ta 2003. A wannan lokacin, shafin yanar gizon da aka sadaukar don samar da bayanai game da ƙararrakin da aka yi da sulhu da aka yi watsi da shi kuma an cire shi.
Kalma daga
Da kara da kamfanonin Synthroid Knoll Pharmaceuticals da kamfanin BASF iyalai ba game da aminci ko ingancin Synthroid ba. Ana amfani da miyagun ƙwayoyi a duk lokacin da ya dace da lafiya. Kotun ta kalubalantar da'awar sayarwa da cewa Synthroid-brand levothyroxine ya kasance mafi kyau ga magunguna na levothyroxine, kuma gaskiyar cewa kamfanin ya cajirci karin don Synthroid bisa ga wannan kuskure.